Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study

• Published in: British journal of clinical pharmacology Vol. 66; no. 5; pp. 695 - 705
• Main Authors: Diav‐Citrin, Orna, Shechtman, Svetlana, Weinbaum, Dafna, Wajnberg, Rebecka, Avgil, Meytal, Di Gianantonio, Elena, Clementi, Maurizio, Weber‐Schoendorfer, Corinna, Schaefer, Christof, Ornoy, Asher
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.11.2008; Blackwell Science Inc
• Subjects: Abnormalities, Drug-Induced - etiology; Abortion, Induced; Adult; Antidepressive Agents, Second-Generation - adverse effects; Antidepressive Agents, Second-Generation - therapeutic use; Birth Weight; cardiovascular anomalies; Case-Control Studies; Confidence Intervals; congenital anomalies; Drug Administration Schedule; Drugs in Pregnancy and Lactation; Female; fluoxetine; Fluoxetine - adverse effects; Fluoxetine - therapeutic use; Gestational Age; Heart Defects, Congenital - etiology; Humans; Infant, Newborn; Maternal Age; Odds Ratio; paroxetine; Paroxetine - adverse effects; Paroxetine - therapeutic use; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Risk; Selective Serotonin Reuptake Inhibitors - adverse effects; Selective Serotonin Reuptake Inhibitors - therapeutic use; SSRI
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1111/j.1365-2125.2008.03261.x

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In recent years there has been concern regarding the possibility that selective serotonin reuptake inhibitors (SSRIs) cause an increased rate of congenital cardiovascular anomalies. • As of today, there is still debate in the literature as to the possible effects of paroxetine and fluoxetine on the embryonic cardiovascular system. WHAT THIS STUDY ADDS • Based on prospective data from three Teratogen Information Services, we have demonstrated an increased rate of congenital cardiovascular anomalies among the offspring of fluoxetine‐ and paroxetine‐treated mothers. AIMS Recent studies have suggested a possible association between maternal use of selective serotonin reuptake inhibitors (SSRIs) in early pregnancy and cardiovascular anomalies. The aim of the present study was to evaluate the teratogenic risk of paroxetine and fluoxetine. METHODS This multicentre, prospective, controlled study evaluated the rate of major congenital anomalies after first‐trimester gestational exposure to paroxetine, fluoxetine or nonteratogens. RESULTS We followed up 410 paroxetine, 314 fluoxetine first‐trimester exposed pregnancies and 1467 controls. After exclusion of genetic and cytogenetic anomalies, there was a higher rate of major anomalies in the SSRI groups compared with the controls [paroxetine 18/348 (5.2%), fluoxetine 12/253 (4.7%) and controls 34/1359 (2.5%)]. The main risk applied to cardiovascular anomalies [paroxetine 7/348 (2.0%), crude odds ratio (OR) 3.47, 95% confidence interval (CI) 1.13, 10.58; fluoxetine 7/253 (2.8%), crude OR, 4.81 95% CI 1.56, 14.71; and controls 8/1359 (0.6%)]. On logistic regression analysis only cigarette smoking of ≥10 cigarettes day−1 and fluoxetine exposure were significant variables for cardiovascular anomalies. The adjusted ORs for paroxetine and fluoxetine were 2.66 (95% CI 0.80, 8.90) and 4.47 (95% CI 1.31, 15.27), respectively. CONCLUSION This study suggests a possible association between cardiovascular anomalies and first‐trimester exposure to fluoxetine.